4 °C with control (DMSO) or 20 µM RA190 were subjected to 10-40% (v/v) glycerol gradient centrifugation for 15 hr at 4 °C. 800 µL fractions were collected and alternate fractions (1, 3, 5, 7, 9, 11, 13, 15, 17) were analyzed for the presence of proteasomal proteins (RPN13, RPN2, RPN1 and UCH37) by Western blot analysis. 148.5 ± 2.12 147.5 ± 0.70 K (Potassium) 6.1 ± 0.14 6.05 ± 0.21 Cl (Chloride) 120.5 ± 2.12 120 ± 1.4 EI-MS profiles were obtained using a Bruker Esquire 3000 plus. Crude compounds were purified by semi-preparative reversed phase HPLC using a Water Delta Prep 4000 system with a Phenomenex column C18 (30 X 4 cm, 300 A, 15 μm spherical particle size column).
Preparation of RA series candidate inhibitors:
Reagents and conditions: (a) AcOH, dry HCl gas, room temperature, overnight (b) Boc or Fmoc protected amino acid, HOBt, HBTU, DMF, DIPEA, room temperature, 3 hr (c) 20% piperidine in
Compounds in Table S1 were synthesized following the strategy reported in methods utilizing classical solution phase reactions. Substituted benzaldehyde (s) II (2.0 mmol) was added to a suspension of 4-piperidone hydrochloride monohydrate I (1.0 mmol) in glacial acetic acid (15 mL). Dry hydrogen chloride gas was passed through this mixture for 0.5 hr during which time a clear solution was obtained. After standing at room temperature for 24 hr, the precipitate (AcOH salt of benzylidine piperidone) III was collected and dried under the vacuum. Target compound (s) IV were synthesized by reacting corresponding compound (s) III and corresponding amino acids in the presence of peptide coupling agents. All the compounds were purified by HPLC and characterized by MS and NMR. For the deprotection of Boc functionality, 4M HCl in dioxane solution was used.
Chemical structures of RA compounds. Chalcones are Michael acceptors and thus their activity is modulated by electron withdrawing/donating character of substituents at the ortho and para positions of the aromatic ring. Therefore in the present study the chalcone functionality has been attached to a piperidone nucleus. We generated a new bis-benzylidine piperidone scaffold that incorporates two Michael enones in a single molecule and introduced different substituents in the aromatic ring to modulate the acceptor character of the enone system of chalcones. Using this strategy, a series of compounds was synthesized by incorporating halogens at ortho and para positions and different amino acids at the amine functionality of 4-piperidone. Since our previous work suggested the importance of phenylalanine at the amine functionality of 4-piperidone for proteasome inhibitory activity (Bazzaro et al., 2011), we derived a majority of RA compounds by incorporating phenylalanine and/or substituted phenylalanine at the same position along with the halogen substituents in the aromatic rings. To overcome the poor solubility and pharmacokinetics of our previous generation molecules, we employed an amide in lieu of a urea linkage between amino acids and 4-piperidone. We synthesized RA166 and RA201 with halogens chlorine and fluorine at the ortho position of aromatic rings and phenylalanine attached to the 4-piperidone. Our prior molecular modeling studies suggested the importance of having two chlorine atoms on one phenyl moiety and thus we synthesized RA190, RA190Ac which possess differences in the phenylalanine and amide conjugation as opposed to the urea conjugation of our first generation molecule RA1 (Bazzaro et al., 2011) . To gain insight into the importance of phenylalanine, we synthesized compounds RA196 and RA213 in which histidine and tyrosine are substituted for phenylalanine, and RA181, which has no substituent.
Structures for RA190B and RA190ME are also provided. 4, 174.9, 143.7, 141.5, 139.2, 138.3, 135.6, 131.7, 129.9, 128.6, 127.1, 125.3, 54.7, 46.9, 42 Cell surface HSP90 staining: Cell surface HSP90 was detected by staining with purified anti-HSP90 mAb (Stressgen), followed by PE-conjugated anti-mouse IgG1. The data were acquired with a FACSCalibur and analyzed using CellQuest software. NMR spectroscopy: NMR spectra were acquired at 25 °C or 10 °C on Bruker NMR spectrometers operating at 850 or 900 MHz and equipped with cryogenically cooled probes.
Antibodies and Western Blot
Processing was performed in NMRPipe (Delaglio et al., 1995) and the resulting spectra visualized with XEASY (Bartels et al., 1995) . Protein concentrations were calculated by extinction coefficients based on amino acid composition and absorbance at 280 nm for protein dissolved in 6 M guanidine-HCl. Buffer A (20 mM NaPO 4 , pH 6.5, 50 mM NaCl, 2 mM DTT, 0.1% NaN 3 , and 5% D 2 O) was used for all NMR samples except those containing RA190, which were performed in Buffer B (Buffer A with no DTT present). 10-fold molar excess RA190 (5 mM stock in DMSO) was incubated with RPN13 protein at 4°C overnight and unreacted RA190 removed by dialysis.
LC high resolution mass spectrometry: RPN13 Pru domain and RA190-exposed RPN13, RPN13 Pru domain, RPN13 Pru C 60, 80, 121 A, and RPN13 Pru C88A at protein concentrations of 1 μg/μL were treated with formic acid and injected onto a Nano2D-LC HPLC system (Eksigent, Dublin, CA) equipped with an Agilent Zorbax 300SB C8 column (3 mm ID, 10 cm length, 3.5 μm particle size). The samples were subjected to 10 min of incubation in 98% H 2 O:2% CH 3 CN, a 20 min linear gradient at 10 μL/min flow rate to 75% H 2 O:25% CH 3 CN followed by a 12 min linear gradient to 5% H 2 O:95% CH 3 CN and then a 2 min hold. Analysis was conducted by positive ionization electrospray with an LTQ-Orbitrap Velos instrument (Thermo Scientific, Waltham, MA) and adducts were quantified utilizing the Orbitrap detector with a resolution of 100,000 at a scan range of 400 -2000 m/z.
RPN13 Pru~RA190 complex calculation:
The RPN13 Pru~RA190 complexes were generated by using HADDOCK 2.1 (High Ambiguity Driven protein-protein DOCKing) (Dominguez et al., 2003) in combination with CNS (Brunger et al., 1998) . A homology model of RPN13 Pru domain was generated by Schrödinger based on the atomic coordinates of murine RPN13 Pru domain (PDB entry 2R2Y) (Schreiner et al., 2008) . Four distance restraints were defined between C88
Sγ of RPN13 and four atoms of RA190 to recapitulate the sulfur-carbon bond ( Figure S4B and S4C); HADDOCK requires two distinct molecules for docking. The ratio of peak intensity values (Δ) were plotted for each RPN13 backbone ( Figure 4A ) and side chain ( Figure 4B ) amide group according to Equation 1, in which Ι represents peak intensity and 0.588 is a scaling factor derived by setting the randomly coiled N and C terminal ends of RPN13 Pru domain as unaffected by RA190.
(1) RPN13 Pru residues with Δ values greater than one standard deviation value above average were defined as "active" and their neighbors as "passive" provided they have >40% accessibility. Ambiguous Interaction Restraints (AIRs) were imposed to restrict hRPN13 Pru active residues to be within 2.0 Å of any RA190 atom (Dominguez et al., 2003) . 1000 structures were subjected to rigid-body energy minimization and the 250 lowest energy structures chosen for semi-flexible simulated annealing in torsion angle space followed by refinement in explicit water. During semi-flexible simulated annealing, atoms at the interface were allowed to move, but constrained by the AIRs and unambiguous distance constraints defining the sulfur-carbon bond. After water refinement, the RMSD of RA190 in the resulting 250 structures was 3.81 ± 0.60 Å and these were sorted into four clusters by using a 1.5 Å cut-off criterion. The lowest energy structure of each cluster was energy minimized by Schrödinger after the explicit introduction of a covalent bond between RPN13 C88 Sγ and RA190 reacted carbon ( Figure   S4B and S4C).
Statistics for human RPN13~RA190 structures sorted into four clusters by using a 1.5 Å cut-off criterion.
Cluster No.
Number of Structures
Haddock score Pharmacokinetic parameters were summarized using descriptive statistics.
RMSD
Complete blood count and blood chemistry analyses: After carbon dioxide euthanasia, 500 to 600 μL blood was collected from each mouse by intracardiac aspiration with a 25-gauge needle and 1-mL syringe. Blood was placed in a 600 μL centrifuge tube coated with lithium heparin to prevent clotting. A complete blood count was performed with an automated hemocytometer (Hemavet HV950FS, Drew Scientific, Oxford, CT). The remaining blood was centrifuged and the plasma drawn off and analyzed with an automated clinical chemistry analyzer (VeTACE, Alfa Wassermann, West Caldwell, NJ).
In vivo DNA delivery: Gene gun particle-mediated DNA delivery was performed using a helium-driven gene gun (Bio-Rad, Hercules, CA) as described previously (Trimble et al., 2003) . 
